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S_mnary Topoisomerase II is a key target for several anti-cancer drugs used for breast cancer therapy,
including doxorubicin, epirubicin and mitoxantrone. Two isoforms of topoisomerase II (x and /) have been
described in human cells which differ in their subcellular localisation, biochemical properties and susceptibility
to inhibition by anti-cancer drugs. The relative level of expression of the x and isoforms may contribute to
the degree of tumour responsiveness to different chemotherapeutic agents. To assess the relationship between
expression of topoisomerase II isoforms and established prognostic factors and pathological variables, 56
primary breast tumour samples were studied. The expression of the two topoisomerase II genes was apparently
not co-ordinately regulated in these tissue samples. There was no relationship between any of the commonly
used pathological variables [tumour size, lymph node status, S-phase fraction (SPF)] and the level ofexpression
of topoisomerase II mRNA. However, high topoisomerase 112 gene expression was significantly associated
with a high SPF (sign-rank test; P=0.01). Moreover, the ratio of mRNA levels for topoisomerase I12 and
showed a stronger relationship to SPF (median ratio 0.62 for tumours with SPF 10, and 1.64 for SPF> 10;
P=0.0021, sign-rankl test). As expected from previous studies, an SPF> 10 was associated with poor overall
survival (P=0.01). Immunohistochemical analysis revealed that topoisomerase II was widely distributed
(>90% positive tumour cells), but that topoisomerase H2 expression was less widely expressed, with a pattern
ofexpression similar to that of the proliferation-dependent antigen recognised by Ki67. Because topoisomerase
II gene expression showed a log-normal distribution, log-transformed data were used in multivariate analysis of
relapse-free survivaL This showed that lymph node status and topoisomerase II mRNA expression were the
only significant survival factors (P=0.001 and 0.05, respectively, with relative risks of 1.3 and 1.8). These
results indicate that topoisomerase W1, but not /3, expression is dependent upon cellular proliferation status,
but that the more widely expressed topoisomerase II protein may play a significant role as a target for anti-
tumour therapy.
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There is an extensive body of work detailing the potential
value of prognostic markers in breast cancer. The major
objective of such studies is to separate patients into low- and
high-risk categories permitting effort to be concentrated on
those patients in the latter category. Such an approach has
been found useful in determining the benefits of chemother-
apy, such as the combination of cyclophosphamide,
methotrexate and 5-fluorouracil (CMF), in patients with
affected regional lymph nodes (Early Breast Cancer Thallists'
Group, 1992). The standard prognostic indices that have been
assessed in node-negative breast cancer are tumour size,
histological classification, nuclear grade, oestrogen and
progesterone receptor status, DNA ploidy and S-phase
fraction (SPF; reviewed by McGuire and Clark, 1992).
There is also evidence that cathepsin D levels, epidermal
growth factor receptor (EGFR) status and the presence ofthe
HER/neu oncogene may be of some prognostic value
(reviewed by Gasparini et al., 1993). Recently, expression of
p53 protein has been shown to be associated with a high
tumour proliferation rate, early disease recurrence and early
death in node-negative breast cancer patients (Allred et al.,
1993). In addition to the identification of prognostic factors,
there is a clear need for predictive markers that will permit
both the development of more appropriate adjuvant
chemotherapy and the selection of those patients most likely
to respond to a particular drug regimen.
A potential prognostic indicator that could also be
predictive of response to chemotherapy is the level of
expression of topoisomerase II. This essential nuclear
enzyme is the primary cellular target for several of the most
effective anti-tumour agents including doxorubicin, etoposide,
epirubicin and mitoxantrone (reviewed by Smith, 1990;
Osheroff et al., 1991; Beck et al., 1993; Pommier, 1993;
Watt and Hickson, 1994). Topoisomerases catalyse the
interconversion of topological isomers of DNA. The type II
topoisomerases, such as topoisomerase II, act via the
introduction of a transient double-stranded break in one
segment of a DNA molecule through which a second DNA
duplex is passed before religation of the break. In
mammalian cells, a role for topoisomerase II has been
suggested in DNA replication, recombination and possibly
transcription, as well as in mitotic chromosome condensation
and segregation (reviewed by Osheroff et al., 1991; Wang,
1985; Watt and Hickson, 1994). Topoisomerase II is also a
structural component of the interphase nucleus, possibly
anchoring looped domains of chromatin to the nuclear
scaffold or matrix (Earnshaw et al., 1985; reviewed by
Roberge and Gasser, 1992).
Topoisomerase II protein levels are markedly higher in
exponentially growing than in quiescent cell lines in tissue
culture, and can be down-regulated by growth ofcells at high
density or in serum-free conditions (Hsiang et al., 1988).
Thus, topoisomerase II may be regarded as a marker of cell
proliferation. Moreover, cells induced to differentiate show
progressively reduced levels of topoisomerase II activity
(Constantinou et al., 1989; Zwelling et al., 1990).
Two distinct isoforms of topoisomerase II exist in human
cells, termed x (170 kDa form) and (180 kDa form), which
differ not only in molecular weight but also in their patterns
of expression and their apparent sensitivity to anti-neoplastic
drugs (Drake et al., 1989; Chung et al., 1989; Woessner et al.,
1990; Jenkins et al., 1992; Austin et al., 1993). In cell lines,
the expression of the z isoform has been shown to be strictly
proliferation dependent, whereas the 0 isoform is present in
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both dividing and non-dividing cells (Woessner et al.. 1991).
However, this pattern ofexpression may not be maintained in
vivo, since it has been reported that lymphocytes induced to
proliferate by exposure to proliferating human antigen (PHA)
show increased expression of both the x and / isoforms
(Kaufmann et al., 1994; Prosperi et al., 1994).
Work on cell lines has shown that the levels of the
topoisomerase IIx and/or /3 mRNAs may decrease in cells
made resistant to topoisomerase II inhibitory drugs, and that
such changes may account for the decreased levels of protein
found in cell lines expressing the so-called 'atypical' multi-
drug resistant phenotype (reviewed by Beck et al., 1993;
Pojumier, 1993). There are documented decreases in both
topoisomerase IIx and topoisomerase II/ protein in such
resistant cell lines. Several studies have shown a correlation
between topoisomerase II protein levels and sensitivity of
cells to these drugs, with elevated levels conferring relative
drug sensitivity and low levels conferring resistance (Davies et
al., 1988; Potmesil et al., 1988; Webb et al., 1991; reviewed by
Beck et al., 1993). Similarly, teratoma cell lines with a greater
sensitivity than bladder cell lines to topoisomerase II poisons
have been shown to express a correspondingly higher level of
topoisomerase II protein (Fry et al., 1991).
Topoisomerase II inhibitors such as doxorubicin, epirubi-
cin and mitoxantrone are widely used in therapy for breast
cancer. The aim of this study was to quantify the level of
expression of the two topoisomerase II isoforms in breast
tumour biopsies and to investigate whether a relationship
exists between the level of topoisomerase II gene protein
expression and the established prognostic indicators for
patient survival.
Materials and methods
Preparation ofmRNA
Tumour samples were obtained from patients undergoing
breast surgery at the John Radcliffe Hospital, Oxford, UK,
and were histologically confirmed as intraductal carcinomas.
Samples were snap frozen and stored in liquid nitrogen
before extraction of total cellular RNA by the method of
Chomczynski and Sacchi, (1987). RNA concentration was
quantified by measurement of optical density at 260 nm.
Integrity of RNA was assessed by running samples on 1%
agarose gels followed by staining with ethidium bromide.
Ribonuclease protection assays
Ribonuclease protection assays were carried out as described
by Jenkins et al. (1992). Topoisomerase IIb and / antisense
RNA probes were prepared as described previously (Davies
et al., 1993). The topoisomerase 112- and #-specific probes
generated 215 bp and 228/292 bp (two splice variants termed
/3-1 and /-2) protected fragments respectively. In each
reaction an internal loading control of an antisense
transcript to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used (producing a 120 bp protected frag-
ment). Quantification of image intensities and autoradio-
grams was performed using a Bio-Image analyser (MilliGen/
BioSearch).
DNA flow cvtometrv
Nuclei were extracted from a 50 pm paraffin-embedded tissue
section for each tumour as described previously (Camplejohn
et al., 1989). Briefly, each section was dewaxed, rehydrated
and was treated for 30 min at 3TC with pepsin, pH 1.5.
Debris was removed by filtration through a 35 pm pore size
nylon gauze and the nuclei were stained with a DNA-specific
dye DAPI at a concentration of I pg ml-'. DNA content in
at least 105 nuclei was measured on a Becton-Dickinson
FACS analyser. DNA aneuploidy was recorded only it two
distinct GI peaks were evident. S-phase fraction (SPF) for
diploid tumours was calculated by the method of Baisch et al.
(1975). and by a modification of this method for aneuploid
tumours as described previously (Camplejohn et al., 1989).
Immunohistochemistrv stainingfor topoisomerase IIx and /
Breast tumour biopsies were obtained fresh after surgery and
representative areas were cut and snap frozen. Cryostat
sections (8 pm) were cut and mounted onto poly-L-lysine-
coated glass slides. After drying for 0.5 to 8 h, the sections
were fixed in phosphate-buffered saline containing 3.7%
formalin for 15 min at room temperature, and then
immediately stained using the immunoperoxidase 'Duet' kit
(Dako). The antibodies used were as follows: the topoisome-
rase lb-specific rabbit polyclonal antiserum termed CRB
(Cambridge Research Biochemicals) which has been used in
previous studies (Smith and Makinson, 1989; Wells et al.,
1994). The topoisomerase Il/-specific mouse monoclonal
antibody designated 3H10 was kindly supplied by Dr A
Kikuchi. This antibody was raised to a peptide in the C-
terminal domain of mouse topoisomerase 11/ protein and
recognises a single 180 kDa protein in human cell extracts (A
Kikuchi, personal communication; H Turley, in preparation).
Moreover, the extensive down-regulation of topoisomerase
Hp protein in a mitoxantrone-resistant CEM cell line,
compared with its parental CEM cell line, is detected by
this antibody (unpublished data). The Ki67 antibody
recognises an antigen expressed exclusively in proliferating
cells and has been used previously as a marker of
proliferation in immunohistochemical studies (Gerdes et al.,
1984; Verheijen, 1989; Gerdes et al., 1991). Staining with
Ki67 was performed after fixing the sections in acetone at
room temperature for 10 min and drying.
The staining was graded by the percentage of tumour cells
expressing topoisomerase 11b as follows: grade 1 (<5%),
grade 2 (5-25%), grade 3 (25-50%) and grade 4 (75%).
This also applied to staining with the Ki67 antibody. Since
nearly all tumour cells stained for topoisomerase lip,
intensity alone was graded as 1+. 2+ or 3+.
Hormone receptors
Oestrogen and EGF receptors were measured by ligand
binding on tumour cytosols and membranes respectively, as
described previously (Harris et al., 1989; Smith et al., 1993).
Patients' characteristics
Patients were treated by wide local excision or simple
mastectomy and node sampling was performed in all cases.
Post-operative radiation therapy was given to the breast after
local excision and to the axilla if lymph nodes were positive.
Adjuvant tamoxifen (20 mg daily) was given to all women
aged 50 or over, whereas six courses of adjuvant CMF
therapy were given to all node-positive patients under 50.
Node-negative patients under 50, with tumours larger than
5 cm, or those with vascular invasion, were also treated with
CMF. The patients were seen at 3 month intervals for the
first 2 years, 6 monthly during the third year and once yearly
thereafter. Patient variables are shown in Table I. Survival
analyses was by the Kaplan-Meier method. with Cox
multivariate analyses.
Resuls
Expression of topoisomerase Iz and / mRNAs
Previous studies have shown that acquired resistance to
topoisomerase II inhibitors can be correlated with down-
regulation of topoisomerase II gene expression. Conversely,
overexpression of topoisomerase II confers relative drug
sensitivity in cell lines (Davies et al., 1988; Potmesil et al.,
1988; Webb et al., 1991; reviewed by Beck et al., 1993).
Ribonuclease protection assays were used to quantify the
level ofexpression of the topoisomerase IIb and # mRNAs inT_opoisomeae I exprin h bre aew
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56 samples extracted from patients with ductal carcinoma of
the breast. The single topoisomerase Ila mRNA and the two
alternatively spliced topoisomerase IlI (fl-I and f-2) mRNAs
were detected in all tumour samples studied. There was
considerable variability between tumours in the level of
expression of the two topoisomerase II genes. The data from
a representative RNAase protection assay is presented in
Figure 1. The levels of topoisomerase II mRNAs were
quantified by densitometric scanning of early exposure
autoradiograms within the linear range for radiographic
film. The results were then standardised by comparison with
the level of an internal control of the housekeeping gene,
GAPDH, with the median value defined as 1. Values ranged
from 44 to 0.08 (approximately 500-fold range) for
topoisomerase Ilb mRNA and 16.5 to 0.05 for topoisome-
rase pfl (an approximately 300-fold range).
There was no correlation (P>0.05) between the relative
levels of the topoisomerase Ilz and f mRNAs in individual
tumours (Figure 2). Thus, in some samples with low levels of
topoisomerase I12 mRNA, there were equivalently low levels
of topoisomerase IlI mRNA (such as sample 9; Figure 1),
whereas in other cases with low topoisomerase Ilz mRNA
expression, the level of topoisomerase HfI mRNA was
substantially higher (sample 6; Figure 1). The relative level
of the fl-I and f-2 mRNAs was generally constant in each
sample.
Relation to topoisomerase II mRNA to SPF and ploidy
The tumours were studied with respect to the relationship
between topoisomerase H mRNA expression and SPF. Those
cases with a high SPF (defined as being >10%) showed
significantly higher topoisomerase Ili mRNA that those with
a low SPF (< 10%) (median 1.47 and 0.42 respectively, using
the Mann-Whitney U-test for non-parametric samples;
P=0.01 level). Because the data was log-normally distrib-
uted, the Spearman rank correlation coefficient for log-
topoisomerase Ili vs SPF was performed (Figure 3), and
showed a correlation coefficient of 0.33 (P=0.01). Using the
median densitometric value of 1 to separate the cases on the
basis of topoisomerase Ila mRNA content, it was found that
SPF was significantly higher in those with topoisomerase Ila
values above the median (P=0.03; Fisher's exact test).
However, there was no relationship between SPF and the
level of the topoisomerase IlI mRNA or log topoisomerase
II#f mRNA (data not shown). The SPF was more highly
related to the ratio of topoisomerase Ili to f mRNA than to
topoisomerase Hzx mRNA level alone (Figure 4) (SPF<10,
median ratio z/fl=0.62; SPF>10 ratio 2/P=1.64, P=0.002
ranked sum test). No correlation was found between the
Table I Patient and tumour characteristics
Variable No. of cases
Age (years)
<50 22
. 50 34
Size (cm)
<2 15
>2 41
Nodes
Negative 30
Positive 26
SPF (%)
<10 33
>10 23
ER (fmolmg-' protein)
<10 18
>10 38
EGFR (fmolmg ') membrane protein
<20 27
>20 29
1 2 3 4 5 6 7 8 9 10 111213 141516 17MWvm bp
Topo 1I-2w
Topo 10-1o
Topo la 1-
GAPDH 8
6 271/281
I
194
118
Fugwe 1 RNAase protection assays of topoisomerase 11x and fi
mRNA levels (and a GAPDH internal control) in breast tumour
biopsies. Lanes 1 through 17 show RNAs from different tumour
samples. The positions of the topoisomerase HIz, l-I, f-2 and
GAPDH protected fragments are shown on the left. The lane
marked MWM contains molecular weight standards which were
run in parallel. The sizes of the standards are shown on the right
(in base pairs). Densitometric scanning of autoradiograms was
performed when each signal was within the linear range for
radiographic film.
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Figwe 2 Topoisomerase 11x vs topoisomerase HPf expression in
human primary breast cancers. RNA was quantitated by
densitometry after RNAase analysis and corrected for GAPDH
expression. Log-transformed results are shown.
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Figwe 4 The ratio of topoisomerase IIx to f mRNA vs S-phase
fraction in primary breast cancers.
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qe _ _degree of tumour ploidy and the level of expression of either
topoisomerase IIb or 3 mRNA using a Mann-Whitney
analysis (data not shown). Ploidy was also compared as a
bivariable (diploid/aneuploid) and as a continuous variable,
but was not significantly associated with topoisomerase Ilo or
P mRNA expression.
Topoisomerase II expression and prognosis
There was no relationship between topoisomerase 112 mRNA
expression, stratified as above or below the median level of 1,
and age, nodal status, tumour size or oestrogen and
epidermal growth factor receptor levels (data not shown).
Similar analyses were performed for topoisomerase IlI, but
the P-values for all of these analyses were above 0.05. Over
the 5 year period since this study was initiated, the overall
level of patient survival has declined to 75% at 5 years
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l
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(actuarial analysis). Those patients with an SPF of greater
than 10 showed a significant (P=0.014) reduction in survival
probability relative to those patients with an SPF of less than
10 (Figure 5). Thus, this group of patients, although
relatively small in number, is representative of previously
reported associations of SPF with overall survival. In a
multivariate analysis of relapse-free survival, lymph node
status was the major independent factor (P=0.001, relative
risk 1.33, confidence intervals 1.12-1.58). However, upon
analysis of many other factors, including age, tumour size,
lymph node involvement, SPF and log topoisomerase 117 and
f mRNA expression, only expression of topoisomerase IIT
mRNA was of additional prognostic significance (P=0.05,
risk of 1.81, confidence interval 1-3.3).
Toposiomerase II protein expression
To assess the relationship between expression of mRNA and
protein for topoisomerase IIz and /, immunocytochemical
analysis was conducted on ten cases with SPF> 11 (median
SPF<10 16) and ten cases with SPF<6.5 (median 3.5) using isozyme- specific antisera. Figure 6 shows a representative tumour
--SPF>10 section stained with anti-topoisomerase 112 and 0 antibodies.
In all cases studied, topoisomerase IT/i protein expression was
very widely distributed in both tumour tissue and surround-
ing stroma. In contrast, a significant level of staining for
topoisomerase II2 protein was seen only in a limited
proportion of the tumour cells and was absent from the
60 72 surrounding stroma.
The percentage of tumour cells staining positively for the
Ki67 antigen correlated well with the distribution of cells
nts stratified by staining positive for topoisomerase IIz protein (P= 0.01), but
not with the intensity of topoisomerase II/i staining. Intensity
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Fugue 6 Immunoperoxidase staining of cryostat sections of breast carcinomas biopsies with anti-topoisomerase IIx (a and c) and
(b and d) antibodies. a and b represent a biopsy with an SPF of 17.3% while c and d represent a biopsy with an SPF of 4.5%. Note
the near absence of positive staining for topoisomerase 11x (but not fi) in the biopsy with the lower SPF.
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of staining for topoisomerase II,B was not related to the
percentage of cells staining positively for topoisomerase 1Ix
protein. In all of the cases, the percentage of cells staining
positive for topoisomerase IlI exceeded that staining positive
for topoisomerase 112. The staining intensity and proportion
ofcells staining positive did not correlate closely with mRNA
levels for either isoform.
Dis~
The aim of this study was to determine the expression of
topoisomerase II isoforms in clinical samples from patients
with breast cancer and to determine whether there was any
correlation between expression of either isoform and number
of different prognostic markers.
In recent years, numerous studies have been carried out to
assess the benefit of measuring the SPF (representing the
percentage of cells in active DNA synthesis) in breast cancer
as a prognostic marker. Most studies have shown an
association between high SPF and relapse-free survival. The
evidence for a link between tumour ploidy and relapse-free
survival has been far less clear cut (reviewed by O'Reilly and
Richards, 1992). The majority of the previous studies have
looked at both node-negative and node-positive cancers. For
example, a study ofpatients with node-negative breast cancer
found that those patients with tumours of greater than
1.0 cm, and with an SPF above 10%, had a 5 year relapse-
free survival of 52%, whereas those with tumours with an
SPF below 10% had a 5 year relapse-free survival of 78%
(for tumours greater than 1 cm) or 96% (tumours less than
1 cm) (O'Reilly et al., 1990). Although other studies have
confirmed the link between SPF and disease-free survival, the
relative survival difference reported has varied between
studies. For example, one study of 398 patients showed
only a 10% difference in survival between patients whose
tumours had low or high SPF (Fisher et al., 1991). An SPF
of 10% as a discriminator has been widely used to distinguish
groups of patients and for that reason we used this value in
our study. A correlation was found between tumours
expressing high topoisomerase 112 mRNA level and high
SPF (defined as being above 10%). Some of the samples
analysed expressed topoisomerase 11x mRNA levels more
than 20 times the median level. Among these were tumours
with an SPF above 15%. Moreover, one of the samples is
known to show gene amplification at the topoisomerase IIa
locus (Smith et al., 1993).
We had thought that there might be an association
between topoisomerase II gene expression and the degree of
ploidy in tumours in view of the role of topoisomerase II in
chromosome structure and dynamics (reviewed by Wang,
1985; Roberge and Gasser, 1992; Watt and Hickson, 1994).
However, there was no correlation between tumour ploidy
and expression of either isozyme. Moreover, there was also
no correlation between levels of topoisomerase II and either
hormone receptor status or tumour size. In our study, the
levels of the two topoisomerase II isoforms varied
significantly between different tumours with a more than
200-fold variation in expression between the highest and
lowest expressors for each isozyme. Despite this, no pattern
was found which might suggest that the topoisomerase HIz
and / genes are coordinately regulated in breast tumours.
Indeed, Jenkins et al. (1992) have shown that the
topoisomerase Ila and / genes are apparently independently
regulated in cell lines.
A small study comparing topoisomerase Ilk mRNA by
dot-blot analysis found that expression was high in nine out
of ten tumour samples studied but was detectable in only
50% of adjacent normal tissues (Kim et al., 1991). Levels of
topoisomerase II expression were also studied in chronic
lymphocytic and acute leukaemias by slot-blot analysis with
high levels of topoisomerase II in acute leukaemias (Gekeler
et al., 1992). A study investigating topoisomerase I,
topoisomerase II, MDR and glutathione S-transferase-7r
mRNA expression failed to detect any topoisomerase H
(presumably z) mRNA in samples of myeloma cells
(Ishikawa et al., 1993). This last study used Northern
blotting which is less sensitive than the ribonuclease
protection assay used here. Our study, unlike the other
investigations, determined the differential expression of the
two topoisomersae II isoforms. D'Andrea et al. (1994)
studied eight breast cancers and found a good correlation
between expression of Ki67 and topoisomerase Mr. Using an
antibody to topoisomerase II#, that does not detect the full-
sized topoisomerase IIi protein, these authors found no
association between the degree of staining for the topoisome-
rase 112 and / proteins.
An increase in mRNA may be secondary to amplification
of topoisomerase II genes. A study of 117 primary breast
cancers found amplification of erbB-2, which is located close
to the topoisomerase 112 locus, in 25 cases and coamplifica-
tion with the topoisomerase IIx gene in three cases (Smith et
al., 1993). Amplification of the topoisomerase Ili locus was
not found. In the cultured cell line SKBr-3, amplification of
erbB-2 was also associated with topoisomerase IlI amplifica-
tion; this line also showed increased sensitivity to the
topoisomerase II inhibitors m-AMSA and mitoxantrone.
These examples indicate that an increase in topoisomerase
II mRNA could reflect genetic changes within a tumour
(Keith et al., 1993).
In our multivariate analysis, a high level of topoisomerase
Ilp mRNA expression was associated with a higher risk of
relapse. However, the significance was borderline and there
was no association with other factors that might provide an
explanation for this. It might have been expected that a
decrease in topoisomerase 1I1l gene expression would be
needed to generate a drug-resistant tissue, assuming that this
isozyme is a significant target for drugs in vivo. However, if
topoisomerase Il/ is relatively drug resistant compared with
topoisomerase IIk in vivo, as has been demonstrated in vitro
(Drake et al., 1989), it is possible that tumours expressing a
high relative level of topoisomerase Il/ might be more
resistant to topoisomerase H inhibitors than those with a
high level of topoisomerase HI gene expression. Whether the
observed up-regulation of topoisomerase II in some
tumours reflects a stress or stromal response associated with
a more aggressive cellular phenotype is not clear at this stage.
This is currently being assessed in cell lines.
It is clear that the high level of topoisomerase IIx mRNA
seen in cell lines is a reflection of proliferation (Woessner et
al., 1991). In the tumour biopsies analysed in this study,
although topoisomerase 11k expression correlated significantly
with SPF, the number of proliferating cells in each tumour
was quite low compared with cell lines in tissue culture. The
overall level of topoisomerase HIr mRNA expression did not
seem to correlate directly with the proportion of the tumour
cells expressing topoisomerase 112 protein, suggesting that
topoisomerase IIk levels may also be regulated post-
transcriptionally. The intensity of staining for topoisomerase
Il0 did not correlate with the level of topoisomerase Ilp
mRNA, as determined by the ribonuclease protection assay.
Thus, we conclude that measurement of mRNA levels for
either isoform is unlikely to present a true picture of the
overall level of the equivalent protein. This is particularly
important to consider since biopsy samples for analysis of
topoisomerase 1p mRNA will inevitably include some
contaminating stromal tissue that we have shown expresses
this isoform. Equally important is the finding that
topoisomerase II is expressed in only a limited number of
proliferating tumour cells. Thus mRNA determinations for
this isoform in homogenised tumour biopsies may provide a
measure of SPF rather than a true measure of the tumour to
tumour variation in expression of the xisoform.
Hellemans et al. (1995) recently published an immunohis-
tochemical study of topoisomerase HIx expression in ductal
carcinoma of the breast. In agreement with our data, they
observed a highly variable proportion of tumour cells which
expressed topoisomerase 11k protein, with a median level ofT _opoisomese I ess-in bread cance
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topoisomerase Ix expression of 14% in tumour cells (with
many tumours showing >25% positive cells for topoisome-
rase IIx). However, Hellemanns et al. (1995) found a positive
correlation between topoisomerase Ilx protein expression and
nodal status, tumour size and grade, that we did not observe.
SPF was not reported in their study nor was the f isozyme
analysed. What is clear from our study is that topoisomerase
Il/fl gene expression varies greatly among different breast
tumour biopsies, but that topoisomerase IIfl protein is
generally distnrbuted in >90% of all tumour cells,
irrespective of their proliferation status. Whether prolifera-
tion further enhances topoisomerase Hpf expression was not
possible to discern from our study, although it should be
noted that the stromal cells within tumour tissue were
frequently stained more strongly for topoisomerase IIfl than
stromal cells in adjacent normal breast tissue.
Tuccari et al. (1993), using a polyclonal antibody to
topoisomerase IMr, found a correlation of topoisomerase
expression with Ki67, in agreement with our data.
Topoisomerase II enzyme activity has been quantified in
one study of biopsies from various tumour types. In this,
MacLeod et al. (1994) found that topoisomerase II activity
was lower in breast cancers than in several other tumour
types, although the identity of the isozymes responsible for
this activity was not discerned. There was a wide range of
topoisomerase II activities, similar to the range of expression
seen immunochemically.
It is clear that a significant proportion of breast cancers
respond to topoisomerase II inhibitors, even when given as a
single agent. Considering the low proportion of breast
tumour cells in S-phase, or that express high levels of the x
isozyme of topoisomerase II, we would suggest that the I
isozyme may represent a significant (and possibly the
primary) target in vivo for chemotherapeutic agents which
target topoisomerase II. Further studies are required to
confirm this suggestion. In summary, we would suggest that
selection of the subset of patients with tumours expressing a
high level oftopoisomerase IIx and/or f expression treatment
with topoisomerase II inhibitors may improve response rates.
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